The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Killer Acquisitions
Abstract
This paper argues that incumbent firms may acquire innovative targets solely to discontinue the target’s innovation projects and preempt future competition. We call such acquisitions “killer acquisitions.” We develop a model illustrating this phenomenon. Using pharmaceutical industry data, we show that acquired drug projects are less likely to be developed when they overlap with the acquirer’s existing product portfolio, especially when the acquirer’s market power is large because of weak competition or distant patent expiration. Conservative estimates indicate that 5.3%–7.4% of acquisitions in our sample are killer acquisitions. These acquisitions disproportionately occur just below thresholds for antitrust scrutiny.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Costs and Benefits of Ownership: A Theory of Vertical and Lateral Integration
Grossman, S. J., & Hart, O. D. (1986) · Journal of Political Economy · doi:10.1086/261404 · Cited by 9,352
Cragg, J. G., & Zarembka, P. (1975) · The Canadian Journal of Economics · doi:10.2307/134075 · Cited by 8,342
Teece, D. J. (1986) · Research Policy · doi:10.1016/0048-7333(86)90027-2 · Cited by 7,842
Property Rights and the Nature of the Firm
Hart, O., & Moore, J. (1990) · Journal of Political Economy · doi:10.1086/261729 · Cited by 5,364
The Hubris Hypothesis of Corporate Takeovers
Roll, R. (1986) · The Journal of Business · doi:10.1086/296325 · Cited by 3,751
New Evidence and Perspectives on Mergers
Andrade, G., Mitchell, M., & Stafford, E. (2001) · Journal of Economic Perspectives · doi:10.1257/jep.15.2.103 · Cited by 2,798
Do Managerial Objectives Drive Bad Acquisitions?
MORCK, R., SHLEIFER, A., & VISHNY, R. W. (1990) · The Journal of Finance · doi:10.1111/j.1540-6261.1990.tb05079.x · Cited by 1,887
Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery
Henderson, R., & Cockburn, I. (1996) · The RAND Journal of Economics · doi:10.2307/2555791 · Cited by 1,388
Salant, S. W., Switzer, S., & Reynolds, R. J. (1983) · The Quarterly Journal of Economics · doi:10.2307/1885620 · Cited by 1,331
Free Entry and Social Inefficiency
Mankiw, N. G., & Whinston, M. D. (1986) · The RAND Journal of Economics · doi:10.2307/2555627 · Cited by 1,233
Henderson, R. (1993) · The RAND Journal of Economics · doi:10.2307/2555761 · Cited by 1,015
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Adams, C. P., & Brantner, V. V. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.420 · Cited by 907
Maksimovic, V., & Phillips, G. (2001) · The Journal of Finance · doi:10.1111/0022-1082.00398 · Cited by 899
Corporate Innovations and Mergers and Acquisitions
BENA, J., & LI, K. (2014) · The Journal of Finance · doi:10.1111/jofi.12059 · Cited by 869
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Does Going Public Affect Innovation?
BERNSTEIN, S. (2015) · The Journal of Finance · doi:10.1111/jofi.12275 · Cited by 842
Firm boundaries matter: Evidence from conglomerates and R&D activity
Seru, A. (2014) · Journal of Financial Economics · doi:10.1016/j.jfineco.2013.11.001 · Cited by 645
The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry
Lerner, J., & Merges, R. P. (1998) · The Journal of Industrial Economics · doi:10.1111/1467-6451.00066 · Cited by 634
How does hedge fund activism reshape corporate innovation?
Brav, A., Jiang, W., Ma, S., & Tian, X. (2018) · Journal of Financial Economics · doi:10.1016/j.jfineco.2018.06.012 · Cited by 604
Self-citationBrand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
Grabowski, H. G., & Vernon, J. M. (1992) · The Journal of Law and Economics · doi:10.1086/467257 · Cited by 574
Diekmann, A. (1985) · Journal of Conflict Resolution · doi:10.1177/0022002785029004003 · Cited by 480
Pricing in the Market for Anticancer Drugs
Howard, D. H., Bach, P. B., Berndt, E. R., & Conti, R. M. (2015) · Journal of Economic Perspectives · doi:10.1257/jep.29.1.139 · Cited by 444
New evidence on the finite sample properties of propensity score reweighting and matching estimators
Busso, M., DiNardo, J., & McCrary, J. (2014) · Review of Economics and Statistics · doi:10.1162/rest_a_00431 · Cited by 428
Generic Drug Industry Dynamics
Reiffen, D., & Ward, M. R. (2005) · Review of Economics and Statistics · doi:10.1162/0034653053327694 · Cited by 312
Dragon-slaying and ballroom dancing: The private supply of a public good
Bliss, C., & Nalebuff, B. (1984) · Journal of Public Economics · doi:10.1016/0047-2727(84)90041-0 · Cited by 303
The Sale of Ideas: Strategic Disclosure, Property Rights, and Contracting
Anton, J. J., & Yao, D. A. (2002) · Review of Economic Studies · doi:10.1111/1467-937x.t01-1-00020 · Cited by 303
Pharmaceutical Price Controls and Entry Strategies
Kyle, M. K. (2007) · Review of Economics and Statistics · doi:10.1162/rest.89.1.88 · Cited by 297
Spending on new drug development1
Adams, C. P., & Brantner, V. V. (2010) · Health Economics · doi:10.1002/hec.1454 · Cited by 277
Takebe, T., Imai, R., & Ono, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12577 · Cited by 238
Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development
Blume-Kohout, M. E., & Sood, N. (2013) · Journal of Public Economics · doi:10.1016/j.jpubeco.2012.10.003 · Cited by 225
R acing T o I nvest? T he D ynamics of C ompetition in E thical D rug D iscovery
Cockburn, I., & Henderson, R. (1994) · Journal of Economics & Management Strategy · doi:10.1111/j.1430-9134.1994.00481.x · Cited by 225
Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration
Ellison, G., & Ellison, S. F. (2011) · American Economic Journal: Microeconomics · doi:10.1257/mic.3.1.1 · Cited by 219
The Gains from Merger or Collusion in Product-Differentiated Industries
Baker, J. B., & Bresnahan, T. F. (1985) · The Journal of Industrial Economics · doi:10.2307/2098385 · Cited by 217
Market incentives and pharmaceutical innovation
Yin, W. (2008) · Journal of Health Economics · doi:10.1016/j.jhealeco.2008.01.002 · Cited by 188
Igami, M. (2017) · Journal of Political Economy · doi:10.1086/691524 · Cited by 183
Incumbency And R&D Incentives: Licensing The Gale Of Creative Destruction
Gans, J. S., & Stern, S. (2000) · Journal of Economics & Management Strategy · doi:10.1162/105864000567945 · Cited by 176
The Changing Structure Of The Pharmaceutical Industry
Cockburn, I. M. (2004) · Health Affairs · doi:10.1377/hlthaff.23.1.10 · Cited by 172
Dynamic Capabilities and Managing Human Capital
Chatterji, A., & Patro, A. (2014) · Academy of Management Perspectives · doi:10.5465/amp.2013.0111 · Cited by 127
Strategies for product cannibalism
Conner, K. R. (1988) · Strategic Management Journal · doi:10.1002/smj.4250090704 · Cited by 114
Stealth Consolidation: Evidence from an Amendment to the Hart-Scott-Rodino Act
Wollmann, T. (2019) · American Economic Review Insights · doi:10.1257/aeri.20180137 · Cited by 112
Monopoly and the Incentive to Innovate When Adoption Involves Switchover Disruptions
Holmes, T. J., Levine, D. K., & Schmitz, J. A. (2012) · American Economic Journal Microeconomics · doi:10.1257/mic.4.3.1 · Cited by 95
Antitrust Limits on Startup Acquisitions
Bryan, K. A., & Hovenkamp, E. (2019) · Review of Industrial Organization · doi:10.1007/s11151-020-09751-5 · Cited by 77
Business Strategy over the Industry Lifecycle
Baum, J. A. C., & McGahan, A. M. (2004) · Advances in strategic management · doi:10.1016/s0742-3322(2004)21 · Cited by 54
R&D policy, agency costs and innovation in personalized medicine
Yin, W. (2009) · Journal of Health Economics · doi:10.1016/j.jhealeco.2009.06.011 · Cited by 47
Entrepreneurship, Innovation, and Platforms
Furman, J. L., Gawer, A., Silverman, B. S., & Stern, S. (2017) · Emerald Group Publishing Limited eBooks · doi:10.1108/s0742-3322201737 · Cited by 35
Cited by
Edmans, A. (2023) · Financial Management · doi:10.1111/fima.12413 · Cited by 531
Innovating big tech firms and competition policy: favoring dynamic over static competition
Petit, N., & Teece, D. J. (2021) · Industrial and Corporate Change · doi:10.1093/icc/dtab049 · Cited by 109
Mandated Financial Reporting and Corporate Innovation
Breuer, M., Leuz, C., & Vanhaverbeke, S. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3449813 · Cited by 27
Edmans, A. (2022) · doi:10.2139/ssrn.4221990 · Cited by 15
Metadata
- Authors
- Cunningham, C., Ederer, F., & Ma, S.
- Venue
- Journal of Political Economy
- Publisher
- University of Chicago Press
- Published
- 2021-03-01
- Volume
- 129
- Issue
- 3
- Pages
- 649-702
- ISSN
- 0022-3808 (ISSN-L)
- 1537-534X
- OpenAlex
- W4231991048
- Cited by
- 452
- References
- 45
- FWCI
- 39.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.